Currently out of the existing stock ratings of Dennis Ding, 16 are a BUY (64%), 9 are a HOLD (36%).

Dennis Ding

Work Performance Price Targets & Ratings Chart

Analyst Dennis Ding, currently employed at JEFFERIES, carries an average stock price target met ratio of 61.54% that have a potential upside of 25.05% achieved within 140 days.

Dennis Ding’s has documented 50 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FOLD, Amicus Therapeutics at 22-Jan-2026.

Wall Street Analyst Dennis Ding

Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) at 10/17/2022. The price target of $4 was fulfilled within 3 days with a profit of $0.59 (17.3%) receiving and performance score of 57.67.

Average potential price target upside

of $20.43 (35.96%) on RYTM (RHYTHM PHARMACEUTICALS).
of $2.88 (25.2%) on ROIV (ROIVANT SCIENCES LTD).

ABUS Arbutus Biopharma Corp NGM NGM Biopharmaceuticals PRDS Pardes Biosciences ROIV Roivant Sciences Ltd CINC CinCor Pharma CORT Corcept Therapeutics LYRA Lyra Therapeutics SGTX Sigilon Therapeutics ASMB Assembly Biosciences FOLD Amicus Therapeutics MIST Milestone Pharmaceuticals RXRX Recursion Pharmaceuticals RYTM Rhythm Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)